Eye redness drops show promise in large trial
NCT ID NCT06803654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested a new eye drop containing brimonidine and sodium hyaluronate against Lumify for reducing eye redness in 578 adults. Participants used the drops four times daily, and redness was measured over several hours. The goal was to see if the new drop works as well as Lumify.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brimonidine tartrate eye drops with sodium hyaluronate
- What this could lead to
- If it works, this could offer a new option for reducing eye redness that is as effective as Lumify but with added comfort from hyaluronate.
- What could go wrong
- This is a non-inferiority trial, meaning it only aims to show the new drop is not worse than Lumify, not that it is better. Results may not lead to a major improvement over existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR REDNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site 101
Memphis, Tennessee, 38119, United States
-
Site 102
Glendale, California, 91204, United States
-
Site 103
Andover, Massachusetts, 01810, United States
-
Site 104
Newport Beach, California, 92663, United States
-
Site 105
Smyrna, Tennessee, 37167, United States
-
Site 106
Louisville, Kentucky, 40206, United States
-
Site 107
Shelby, North Carolina, 28150, United States
-
Site 108
Garner, North Carolina, 27529, United States
-
Site 109
Pittsburg, Kansas, 66762, United States
-
Site 111
Northbrook, Illinois, 60062, United States
-
Site 112
Cranberry Township, Pennsylvania, 16066, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.